What is the elephant in the room when considering new therapies for fungal diseases?

Author(s)

Chaves, Alison Felipe Alencar ^[1] ; Xander, Patricia ^[2] ; Romera, Lavinia Maria Dal'Mas ^[3] ; Fonseca, Fernando Luiz Affonso ^[2] ; Batista, Wagner Luiz ^{[1, 2]}

Affiliation

^[1] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Microbiol, Sao Paulo - Brazil

• Document type: Review article
• Source: CRITICAL REVIEWS IN MICROBIOLOGY; v. 47, n. 3 JAN 2021.
• Web of Science Citations: 0

Abstract

The global scenario of antimicrobial resistance is alarming, and the development of new drugs has not appeared to make substantial progress. The constraints on drug discovery are due to difficulties in finding new targets for therapy, the high cost of development, and the mismatch between the time of drug introduction in a clinic and microorganism adaptation to a drug. Policies to address neglected diseases miss the broad spectrum of mycosis. Society is not aware of the actual threat represented by fungi to human health, food security, and biodiversity. The evidence discussed here is critical for warning governments to establish effective surveillance policies for fungi. (AU)

• FAPESP's process: 15/09727-6 - Engineering and characterization of a mutant ””PbKU70 for the human pathogenic fungus Paracoccidioides brasiliensis
• Grantee: Alison Felipe Alencar Chaves
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 17/04592-0 - Evaluation of S-nitrosylated proteins of the Paracoccidioides brasiliensis after nitrosative stress and identification of potential redox signaling pathways
• Grantee: Wagner Luiz Batista
• Support Opportunities: Regular Research Grants